Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-OLS long-term safety and efficacy of DaxibotulinumtoxinA in isolated cervical dystonia
2018-000447-11Phase 3Unknown
- Sponsor
- Revance Therapeutics
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in cervical dystonia (CD), sponsored by Revance Therapeutics. Primary endpoint: Dose- and cycle-specific incidence of drug-related adverse events. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on 2018-000447-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000447-11.